

Pneuma Respiratory partners with Leads Biolabs

15 May 2019 | News

Using Pneuma's digital inhaler platform, the agreement provides access to the untapped potential of pulmonary delivery of Leads' immuno-oncology therapies in the treatment of oncologic or immune-mediated lung diseases



Pneuma Respiratory, Inc., developer of a proprietary breath-activated digital inhaler (BDI), and Leads Biolabs Inc. announce an agreement granting Pneuma an exclusive license to develop Leads Biolabs' panel of immuno-oncology monoclonal antibodies and fusion protein molecules for the pulmonary delivery of Leads' antibodies and molecules.

Using Pneuma's digital inhaler platform, the agreement provides access to the untapped potential of pulmonary delivery of Leads' immuno-oncology therapies in the treatment of oncologic or immune-mediated lung diseases.

In a recent publication, Pneuma announced the completion of a study demonstrating the feasibility of antibody delivery to the lungs via its digital inhaler platform. This study, conducted in an animal model, indicates that the Pneuma digital inhaler platform may provide a method for the pulmonary delivery of monoclonal antibody therapies, enabling the targeted treatment of oncologic or immune-mediated lung diseases.

"This collaboration is an exciting development for the field of immuno-oncology," said Ronald Bukowski, MD, physician emeritus, Cleveland Clinic Foundation. "Approaches utilizing the regional administration of novel checkpoint inhibitors may provide new treatment opportunities for patients with a variety of malignancies."

"We are pleased to enter into a license agreement for Leads Biolabs monoclonal antibody portfolio," said Pneuma Chief Executive Officer and co-founder Eric Hunter. "We look forward to working with their team to conduct studies that may lead to positive change in the future treatment of non-small cell lung cancer."